Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Esophageal carcinoma, gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Withdrawn
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Kimmtrak tebentafusp unresectable or metastatic uveal melanoma Reimburse with clinical criteria and/or conditions Complete
Kineret anakinra Still's disease Withdrawn
Kisqali Ribociclib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib HR+, HER2- advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib with Fulvestrant +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Kisqali ribociclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Received